INTESTIFIX 001
Sponsors
Klinikum Der Universitat Munchen AöR, Universitaetsklinikum Heidelberg AöR, Universitaetsklinikum Aachen AöR, Goethe University Frankfurt, Fraunhofer Institute For Translational Medicine And Pharmacology ITMP
Conditions
Crohn's diseaseHepatocellular carcinomaInfections with multidrug-resistant EnterobacteriaceaeIntestinal colonization with vancomycin-resistant enterococci (VRE)Recurrent urinary tract infections (rUTI)cirrhosis and ascites
Phase 1
Phase 2
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab – A randomized, placebo-controlled, double-blind Phase II trial (FLORA)
RecruitingCTIS2023-506887-15-00
Start: 2025-07-14Target: 48Updated: 2026-01-22
Encapsulated Fecal Microbiota Transfer to Treat Immune Activation in Patients with Cirrhosis and Ascites (TransImmune) – A randomized, double-blind, placebo-controlled phase IIa clinical pilot study
RecruitingCTIS2023-507790-18-00
Start: 2025-08-01Target: 24Updated: 2026-01-12
A Randomized controlled open-label phase II trial assessing the efficacy and safety of two-dosing regimens of frozen encapsulated fecal microbiota transfer products with or without an individualized donor selection approach in decolonizing carriers of multi-drug resistant Enterobacteriaceae (RESET-MDR)
RecruitingCTIS2024-519748-34-00
Start: 2026-01-23Target: 76Updated: 2025-10-09
Fecal microbiota transfer for the secondary prevention of recurrent urinary tract infections in premenopausal women: a phase II trial (FEMITRANS)
Not yet recruitingCTIS2025-520452-28-00
Target: 24Updated: 2026-01-07
Randomized Controlled Trial Assessing the Effectiveness and Safety of Fecal Microbiota Transfer for VRE Eradication in Immunocompromised Patients (EU CTR, Phase II) – VRE-ex
Not yet recruitingCTIS2026-525632-41-00
Target: 42Updated: 2026-07-21